A novel treatment for graft versus host disease is showing a lot of promise in new data from a late-breaking abstract presented during American Society of Hematology (ASH) Annual Meeting and Exposition. A team, led by Shernan G. Holtan, MD, University of Minnesota, compared the outcomes of alloHCT in a randomized phase 3 trial of patients treated with a new GVHD treatment compared to standard treatment. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more